65,437 trials
Infusion Reaction · Monoclonal Antibody
Primary: Number of Participants With Standard Infusion Reactions (SIR) at Cycle 1 and During Subsequent Cycles of Monoclonal Antibody Infusion — 14; 26; 4; 35 Participants
Chronic Lymphocytic Leukemia
Primary: Number of Treatment-emergent Adverse Events as Assessed by CTCAE v4.0 — 1; 0; 0; 0 Adverse Events
Basal Blood Flow
Primary: Number of Participants Evaluated to Measure Blood Flow and Oxygenation in the Brachial Artery — 8 Participants
Anesthesia · Pain
Primary: Changes in Cortical Oxyhemoglobin Concentrations to Ablation — 0.170; 0.057; 0.085; 0.157 μM
Mobility Limitation
Primary: Change in Late Life Function and Disability Index (Function Domain Only) — 1.67 units on a scale
Parkinson Disease · Idiopathic Parkinson Disease
Primary: Distribution Volume Ratio — 2.65; 2.70; 2.96; 2.74 Distribution volume ratios — p=0.05
COVID-19
Primary: Groups 2a and 2b and ARCT-154-J01 Historical Control: Geometric Mean Titers (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody…
Cataracts
Primary: Cumulative IOP Spike Rate From Safety Endpoint — 7.54; 7.46 Percentage
Breast Cancer
Primary: Number of Patients With Local Recurrence — 10 participants
Triple Negative Breast Neoplasms
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 32; 59; 2; 53 Participants
Athletic Performance
Primary: Results Obtained in the Physical Tests to Evaluate Impact on Acceleration — 1.76; 2.44; 2.08; 2.19 m/s^2 — p=0.8705
Advanced Hepatocellular Carcinoma
Primary: Percentage of Lesions With Organ-specific Response — 29.8; 28.3; 40.5; 29.1 Percentage of Units (lesions)
Friedreich Ataxia
Primary: Change in High Contrast Visual Acuity — 5.5; 0 Number of Letters Read on a Vision Board
Covid19
Primary: Uptake-Total — 14308; 14381 Participants
OCD · Decision-Making · tDCS
Primary: Strength of Behaving Model-based (Goal-directed) — 0.09; 0.07; -0.08; 0.06 units on a scale